Petkova-Kirova P, Anastassova N, Minchev B, Uzunova D, Grigorova V, Tsvetanova E
Molecules. 2024; 29(23).
PMID: 39683869
PMC: 11643547.
DOI: 10.3390/molecules29235711.
Kumar N, Jangid K, Kumar V, Devi B, Arora T, Mishra J
RSC Med Chem. 2024; .
PMID: 39399311
PMC: 11462584.
DOI: 10.1039/d4md00550c.
Tchekalarova J, Ivanova P, Krushovlieva D, Kortenska L, Angelova V
Int J Mol Sci. 2024; 25(3).
PMID: 38339146
PMC: 10855364.
DOI: 10.3390/ijms25031867.
Zueva I, Vasilieva E, Gaynanova G, Moiseenko A, Burtseva A, Boyko K
Int J Mol Sci. 2023; 24(22).
PMID: 38003588
PMC: 10671303.
DOI: 10.3390/ijms242216395.
El-Maraghy S, Reda A, Essam R, Kortam M
Inflammopharmacology. 2023; 31(5):2701-2717.
PMID: 37598127
PMC: 10518278.
DOI: 10.1007/s10787-023-01292-z.
The human acetylcholinesterase C-terminal T30 peptide activates neuronal growth through alpha 7 nicotinic acetylcholine receptors and the mTOR pathway.
Graur A, Sinclair P, Schneeweis A, Pak D, Kabbani N
Sci Rep. 2023; 13(1):11434.
PMID: 37454238
PMC: 10349870.
DOI: 10.1038/s41598-023-38637-1.
Amyloid-beta aggregation implicates multiple pathways in Alzheimer's disease: Understanding the mechanisms.
Iliyasu M, Musa S, Oladele S, Iliya A
Front Neurosci. 2023; 17:1081938.
PMID: 37113145
PMC: 10128090.
DOI: 10.3389/fnins.2023.1081938.
Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.
Dos Santos Moreira N, Lima J, Marchiori M, Carvalho I, Sakamoto-Hojo E
J Alzheimers Dis Rep. 2022; 6(1):177-193.
PMID: 35591949
PMC: 9108627.
DOI: 10.3233/ADR-210061.
Discovery of Natural Inhibitors of Cholinesterases from : In Vitro and In Silico Approaches.
Hwang J, Youn K, Lim G, Lee J, Kim D, Jun M
Nutrients. 2021; 13(1).
PMID: 33477276
PMC: 7830924.
DOI: 10.3390/nu13010254.
Alzheimer's Disease as a Membrane Disorder: Spatial Cross-Talk Among Beta-Amyloid Peptides, Nicotinic Acetylcholine Receptors and Lipid Rafts.
Fabiani C, Antollini S
Front Cell Neurosci. 2019; 13:309.
PMID: 31379503
PMC: 6657435.
DOI: 10.3389/fncel.2019.00309.
localization of human acetylcholinesterase-derived species in a β-sheet conformation at the core of senile plaques in Alzheimer's disease.
Jean L, Brimijoin S, Vaux D
J Biol Chem. 2019; 294(16):6253-6272.
PMID: 30787102
PMC: 6484111.
DOI: 10.1074/jbc.RA118.006230.
Strategies for Continued Successful Treatment in Patients with Alzheimer's Disease: An Overview of Switching Between Pharmacological Agents.
Blesa R, Toriyama K, Ueda K, Knox S, Grossberg G
Curr Alzheimer Res. 2018; 15(10):964-974.
PMID: 29895249
PMC: 6142408.
DOI: 10.2174/1567205015666180613112040.
Hydroxybenzoic Acid Derivatives as Dual-Target Ligands: Mitochondriotropic Antioxidants and Cholinesterase Inhibitors.
Oliveira C, Cagide F, Teixeira J, Amorim R, Sequeira L, Mesiti F
Front Chem. 2018; 6:126.
PMID: 29740575
PMC: 5924788.
DOI: 10.3389/fchem.2018.00126.
Expression Profiling of Cytokine, Cholinergic Markers, and Amyloid-β Deposition in the APPSWE/PS1dE9 Mouse Model of Alzheimer's Disease Pathology.
Reale M, DAngelo C, Costantini E, Di Nicola M, Yarla N, Kamal M
J Alzheimers Dis. 2018; 62(1):467-476.
PMID: 29439355
PMC: 5817902.
DOI: 10.3233/JAD-170999.
Troxerutin protects hippocampal neurons against amyloid beta-induced oxidative stress and apoptosis.
Farajdokht F, Amani M, Bavil F, Alihemmati A, Mohaddes G, Babri S
EXCLI J. 2017; 16:1081-1089.
PMID: 29285004
PMC: 5735350.
DOI: 10.17179/excli2017-526.
Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.
Macdonald I, Maxwell S, Reid G, Cash M, DeBay D, Darvesh S
J Alzheimers Dis. 2017; 58(2):491-505.
PMID: 28453492
PMC: 5438481.
DOI: 10.3233/JAD-170164.
Immunohistochemical analysis of hippocampal butyrylcholinesterase: Implications for regional vulnerability in Alzheimer's disease.
Mizukami K, Akatsu H, Abrahamson E, Mi Z, Ikonomovic M
Neuropathology. 2015; 36(2):135-45.
PMID: 26293308
PMC: 4761534.
DOI: 10.1111/neup.12241.
Cholinesterase inhibitors for the treatment of Alzheimer's disease:: getting on and staying on.
Grossberg G
Curr Ther Res Clin Exp. 2014; 64(4):216-35.
PMID: 24944370
PMC: 4052996.
DOI: 10.1016/S0011-393X(03)00059-6.
A new motif in the N-terminal of acetylcholinesterase triggers amyloid-β aggregation and deposition.
Hou L, Xu J, Zhao Q, Gao X, Cui Y, Xu J
CNS Neurosci Ther. 2013; 20(1):59-66.
PMID: 23981668
PMC: 6493010.
DOI: 10.1111/cns.12161.
Amyloidosis in Alzheimer's Disease: The Toxicity of Amyloid Beta (A β ), Mechanisms of Its Accumulation and Implications of Medicinal Plants for Therapy.
Prasansuklab A, Tencomnao T
Evid Based Complement Alternat Med. 2013; 2013:413808.
PMID: 23762130
PMC: 3671299.
DOI: 10.1155/2013/413808.